Skip to main content

Advertisement

Table 1 Comparisons of differences between patients with community-acquired K. pneumoniae bacteremia and control group

From: Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniaeinvasive syndrome

  Community-acquired K. pneumoniaebacteremia    
Variable Invasive syndrome (%)    
  Yes (n = 76) No (n = 332) pvalue Control (%) (n = 76) pvalue+
Hypermucoviscosity phenotype of K. pneumoniae 69 (90.8) 78 (23.5) < 0.01*   
Male 40 (52.6) 150 (45.2) 0.25 40 (52.6) 0.99
Age ≥ 60 yrs 39 (51.3) 128 (38.6) 0.05 39 (51.3) 0.99
Diabetes mellitus (DM) 41 (53.9) 134 (40.4) 0.04 25 (32.9) 0.01
DM with poor glycemic control (HbA1c ≥ 9%) 32 (42.1) 75 (22.6) < 0.01* 17 (22.4) 0.02
Cardiovascular diseases 17 (22.4) 65 (19.6) 0.69 21 (27.6) 0.57
Liver cirrhosis 5 (6.6) 45 (13.6) 0.12 10 (13.2) 0.28
Chronic renal failure 10 (13.2) 35 (10.5) 0.54 18 (23.7) 0.14
Malignancy 4 (5.3) 33 (9.9) 0.27 18 (23.7) < 0.01
Biliary tract diseases 2 (2.6) 20 (6.0) 0.39 8 (10.5) 0.10
Absence of underlying diseases 12 (15.8) 44 (13.3) 0.69 9 (11.8) 0.64
Therapy in the month prior to the infection      
  Proton-pump inhibitors 8 (10.5) 24 (7.2) 0.47 15 (19.7) 0.17
  Aspirin 2 (2.6) 56 (16.9) < 0.01* 8 (10.5) 0.10
  Antibiotics 5 (6.6) 28 (8.4) 0.76 12 (15.8) 0.12
  1. +Age-matched analysis (K. pneumoniae invasive syndrome vs. control group).
  2. *Results of multivariate analysis indicated that community-acquired K. pneumoniae bacteremic patients who were infected by strains expressing the hypermucoviscosity phenotype (odds ratio [OR], 31.07; 95% confidence interval [CI], 13.55-71.22; p < 0.01) and diabetic patients with poor glycemic control (OR, 2.46; 95% CI, 1.27-4.77; p < 0.01) were at increased risk, whereas those who had recent therapy with aspirin (OR, 0.17; 95% CI, 0.04-0.79; p = 0.02) were at lower risk of acquiring K. pneumoniae-associated invasive syndrome.